Introduction: The Intersection of Insulin Therapy and Respiratory Medicine

Afrezza (insulin human) inhalation powder represents a unique approach to prandial insulin delivery—one that leverages the extensive surface area of the lungs for rapid systemic absorption. For patients with type 1 or type 2 diabetes who require mealtime insulin, Afrezza offers a needle-free alternative that closely mimics the physiological first-phase insulin response. The device is particularly valuable for individuals with needle phobia, a condition affecting up to one in four adults with diabetes, and for those seeking greater dosing convenience. However, because the drug is administered directly into the respiratory tract, understanding its impact on lung function is essential for safe prescribing and long-term management. This article provides a comprehensive overview of Afrezza’s effects on lung health, covering mechanism, clinical evidence, patient selection, monitoring protocols, and practical considerations.

How Afrezza Works: Rapid Absorption Through the Lungs

Afrezza consists of dry-powder insulin formulated as Technosphere® particles—approximately 2–3 µm in diameter—that dissolve rapidly upon contact with the alveolar epithelium. When inhaled via the small, breath-powered inhaler (the Dreamboat™ device), the particles deposit in the deep lung, where insulin monomers cross into the bloodstream within minutes. Peak serum concentrations occur roughly 12–15 minutes after inhalation, and the duration of action is about 2–3 hours, making Afrezza ideal for controlling postprandial hyperglycemia without causing prolonged hypoglycemia.

This pharmacokinetic profile differs markedly from rapid-acting insulin analogs (e.g., insulin lispro, aspart, glulisine) injected subcutaneously, which typically peak at 30–90 minutes and last 3–5 hours. The lung’s permeability and high vascularization allow for near-immediate absorption, but this route also exposes pulmonary tissue to a foreign protein and excipients (including fumaryl diketopiperazine, or FDKP, a carrier that dissolves at physiological pH). The FDKP particles self-assemble into the Technosphere structure and are largely eliminated via renal filtration; however, a small fraction may be retained in the lung, prompting ongoing investigation into long-term tissue effects. Preclinical studies have shown no evidence of fibrosis or granuloma formation, but clinical monitoring remains mandatory.

Critical Pre-Treatment Assessment: Lung Function Testing

Before initiating Afrezza, current guidelines from the U.S. Food and Drug Administration (FDA) recommend a baseline spirometry test, including forced expiratory volume in one second (FEV₁) and forced vital capacity (FVC). These measurements establish a personal reference point and help identify patients with underlying undiagnosed respiratory impairment. Afrezza is contraindicated in individuals with chronic lung diseases such as asthma or chronic obstructive pulmonary disease (COPD), as well as in current smokers or those who have recently quit smoking (within the past six months). Lung function should be repeated at regular intervals—typically every 6 to 12 months—and more frequently if respiratory symptoms develop.

Interpreting Spirometry Results

A decline in FEV₁ of 20% or more from baseline, or a persistent drop below 70% of predicted normal, should prompt discontinuation of Afrezza and further pulmonary evaluation. In clinical trials, a small but statistically significant mean decline in FEV₁ (approximately 40–50 mL over the first six months) was observed in Afrezza users compared to those using injectable insulin, though this decline tended to stabilize or reverse after discontinuation. Patients with any pre-existing lung condition (even mild intermittent asthma) are excluded from the label indication because of an increased risk of bronchospasm. The American Thoracic Society and European Respiratory Society guidelines for spirometry interpretation should be used to classify severity and change. A repeat test after bronchodilator administration is recommended if any obstruction is suspected.

Common Respiratory Side Effects and Their Management

Even among appropriately selected patients without baseline lung disease, cough is the most frequently reported adverse reaction, occurring in approximately 10–20% of users. The cough is usually mild, dry, and transient, often occurring within seconds to minutes after inhalation. The mechanism likely involves direct irritation of the upper airway by the dry powder, as well as a reflex response to rapid insulin absorption. Strategies to reduce cough include proper inhalation technique (steady, medium-to-fast inhalation through the device without exhaling into it), use of a spacer if the patient has difficulty coordinating, and ensuring the device is kept clean and dry. Throat irritation and pharyngeal pain are also common but typically resolve over time. In persistent cases, switching to a lower dose cartridge for the first few weeks may help the airway adapt.

More concerning is the potential for bronchospasm—a sudden constriction of airway smooth muscle that can cause wheezing, dyspnea, and chest tightness. In pre-marketing studies, bronchospasm rates were low in patients without asthma (less than 1%), but among those with asthma, the incidence surged to 25–30%, leading to the aforementioned contraindication. Patients who develop bronchospasm should discontinue Afrezza immediately, and a short-acting bronchodilator (e.g., albuterol) may be needed. It is important to differentiate bronchospasm from simple cough: bronchospasm involves objective wheezing on auscultation and a drop in peak expiratory flow.

The Clinical Evidence: What Studies Reveal About Pulmonary Safety

The safety of Afrezza on lung function was examined in several key trials. The largest, a 52-week open-label study (NCT01445951), compared Afrezza plus basal insulin to injectable mealtime insulin plus basal insulin in patients with type 1 diabetes. At week 52, the mean change in FEV₁ was -0.09 L for Afrezza versus -0.02 L for comparator—a difference that was statistically significant but not progressive after the first 6 months. No increase in incidence of respiratory infections or new-onset asthma was observed. A separate computed tomography substudy showed no evidence of lung structure abnormalities over 24 months.

Two additional studies (Affinity 1 and Affinity 2) enrolled patients with type 2 diabetes not adequately controlled on oral agents or basal insulin. Results showed similar declines in FEV₁ (mean ~40 mL over 24 weeks) that plateaued thereafter. Importantly, no changes in diffusing capacity for carbon monoxide (DLCO) were reported, suggesting no significant alveolar-capillary membrane damage. Long-term extension data (up to 2 years) indicated that the mild lung function decrement does not worsen over extended use and may partially reverse after discontinuation.

Nevertheless, the FDA mandated a post-marketing safety study (the INHALE-2 trial) that is currently ongoing to further evaluate real-world lung function outcomes, including in older adults and those with mild intermittent asthma. Early real-world data from patient registries indicate that when the drug is used strictly according to labeling (i.e., no pre-existing lung disease, no smoking), serious pulmonary events are rare. A 2023 analysis of more than 8,000 patient-years of exposure found no cases of bronchospasm requiring hospitalization among non-asthmatic users.

Patient Populations Requiring Extra Caution

Beyond asthma and COPD, certain groups warrant heightened vigilance:

  • Acute respiratory illness: Patients with current pneumonia, bronchitis, or severe allergic rhinitis should delay starting Afrezza until symptoms resolve, as airway inflammation can increase insulin absorption variability and the risk of cough. A "washout" period of at least 2 weeks after symptom resolution is prudent.
  • History of pulmonary embolism or interstitial lung disease: These conditions can alter lung perfusion and insulin absorption, and safety data are lacking. Afrezza is not recommended in such cases.
  • Concurrent use of bronchodilators or inhaled corticosteroids: While not contraindicated, co-administration may affect insulin deposition patterns. Inhaled beta-agonists can increase heart rate and should be used with caution in those with cardiovascular risk. Patients using long-acting beta-agonists should take their bronchodilator before Afrezza to maximize airway caliber.
  • Smokers and vapers: Tobacco and cannabis smoking alter airway integrity and ciliary function, significantly increasing the risk of chronic cough and accelerated decline in lung function. The product label recommends not starting Afrezza within 6 months of smoking cessation. Nicotine vapor from e-cigarettes also impairs mucociliary clearance and may increase cough frequency.
  • Elderly patients (≥65 years): Age-related changes in lung elasticity and immune function may heighten sensitivity. In clinical trials, older adults showed a slightly greater mean FEV₁ decline (about 60 mL) compared to younger adults, though no increase in serious respiratory events was observed. Spirometry monitoring every 3–6 months is advisable.
  • Pregnancy and lactation: Afrezza is classified as pregnancy category C (FDA). There are no adequate controlled studies in pregnant women. Because inhaled insulin’s absorption may be altered by pregnancy-related changes in lung function, and because animal studies showed some fetal toxicity at high doses, Afrezza should only be used during pregnancy if the benefit clearly outweighs the risk. Insulin aspart or lispro remain the preferred prandial options during pregnancy.

Monitoring Lung Health During Treatment: A Practical Protocol

For patients who begin Afrezza, a systematic monitoring plan promotes early detection of adverse pulmonary effects:

  1. Baseline spirometry (FEV₁, FVC, FEV₁/FVC ratio) performed within 30 days of starting therapy. Include pre- and post-bronchodilator testing if baseline values are borderline or if the patient has any respiratory symptoms.
  2. First follow-up: After 6 months of treatment, repeat spirometry and assess for any new cough, dyspnea, or wheezing. A symptom questionnaire (e.g., COPD Assessment Test) may be useful even in non-COPD patients.
  3. Annual follow-up: Yearly spirometry thereafter. More frequent testing (e.g., every 3 months) is advised for patients who report respiratory symptoms or who have borderline baseline values (FEV₁ 70–80% predicted).
  4. Patient self-monitoring: Educate patients to recognize signs of bronchospasm (sudden wheezing, chest tightness) and to contact their prescriber immediately if these occur. If any episode of bronchospasm is documented, Afrezza should be discontinued permanently. Home peak flow monitoring using a simple meter can provide early warning; a drop of more than 20% from personal best warrants medical review.
  5. Documentation: Maintain a log of all spirometry results, symptom reports, and any respiratory medication changes. This is crucial for both clinical decision-making and any future regulatory inquiries.

Alternative Insulin Options When Afrezza Is Not Appropriate

For patients who cannot use Afrezza due to pre-existing lung conditions, smoking history, or unacceptable respiratory side effects, several alternatives exist for prandial insulin coverage:

  • Rapid-acting insulin analogs (lispro, aspart, glulisine) injected subcutaneously remain the gold standard. They can be dosed immediately before or after meals and provide predictable glucose-lowering effects. Ultra-rapid formulations (Fiasp® and Lyumjev®) have an onset of 2–4 minutes and a peak similar to Afrezza, though they still require injection.
  • Inhaled insulin (other formulations): Exubera (discontinued due to lung safety concerns) and newer investigational products such as Dance 501 are not currently available in the U.S., leaving Afrezza as the sole approved inhaled insulin. Research into encapsulation and microparticle technologies continues, but none are expected soon.
  • Pre-mixed insulins (e.g., 70/30 or 75/25) offer convenience for some patients with type 2 diabetes who require both basal and prandial coverage, though they lack the flexibility of separate basal-bolus regimens.
  • Non-insulin injectables: GLP-1 receptor agonists such as liraglutide or semaglutide can provide postprandial glucose reductions and weight benefits, but they are not a direct substitute for insulin in type 1 diabetes. For type 2 diabetes, combining a GLP-1 agonist with basal insulin may reduce the need for rapid-acting insulin.
  • Insulin pump therapy: Continuous subcutaneous insulin infusion provides precise prandial dosing with ultra-rapid analogs and is an excellent alternative for patients who desire the convenience of Afrezza but cannot use it.

Practical Tips for Patients New to Afrezza

To optimize both glycemic control and lung health, patients should be instructed in proper device technique:

  • Insert the cartridge firmly into the inhaler, ensuring the foil seal is pierced. A click confirms proper seating.
  • Hold the device horizontally and inhale steadily and deeply (but not forcefully) through the mouthpiece in a single breath. A "slow and steady" inhale over 2–3 seconds is ideal; too rapid an inhalation may deposit particles in the mouth rather than the lungs.
  • Hold the breath for 5 seconds, then exhale normally away from the device.
  • Never exhale into the inhaler, as moisture will degrade the powder. The Dreamboat device is not waterproof; keep it dry.
  • Clean the inhaler mouthpiece daily with a dry cloth. Replace the device every 14 days regardless of use frequency.
  • Store cartridges at room temperature (15–30°C) and protect from moisture. Do not refrigerate or freeze.
  • Monitor peak expiratory flow (PEF) at home using a simple peak flow meter if the patient has a history of mild respiratory symptoms. A drop in PEF of more than 20% from personal best should prompt medical review.
  • If a dose is missed, take it as soon as remembered, but skip if the next meal is within 2 hours to avoid stacking. Never double a dose.

The Role of Healthcare Providers in Shared Decision-Making

Given the unique risk profile of inhaled insulin, prescribers should engage in thorough shared decision-making. The conversation should include a discussion of the patient’s lifestyle (need for needle-free delivery), pulmonary risk factors, ability to perform spirometry, and willingness to adhere to monitoring schedules. For many patients, the convenience of Afrezza—particularly the rapid onset and offset—can improve postprandial control and reduce hypoglycemia compared to injected rapid analogs. However, the requirement for periodic lung function testing and the small risk of pulmonary toxicity must be weighed against these benefits. The cost and insurance coverage also play a role: Afrezza is often more expensive than generic injectable insulins, and prior authorization may be required. A trial period of 2–4 weeks with close follow-up can help determine if the patient tolerates the inhaler and if glycemic targets are met.

Regulatory Warnings and Black-Box Labeling

The FDA-approved prescribing information for Afrezza carries a boxed warning (the strongest level of warning) regarding acute bronchospasm in patients with chronic lung disease. The warning states: "Afrezza is contraindicated in patients with chronic lung disease such as asthma or COPD. Acute bronchospasm has been observed in patients with these conditions. Before starting Afrezza, perform a detailed medical history, physical examination, and spirometry to identify potential underlying lung disease." This labeling underscores the non-negotiable nature of pre-treatment pulmonary screening. The FDA also requires a Medication Guide to be dispensed with each prescription, explaining the risks in plain language.

Post-marketing surveillance since 2015 has not identified any new safety signals beyond those seen in clinical trials. However, the FDA continues to monitor through the Adverse Event Reporting System. Any clinician encountering a serious event such as bronchospasm, respiratory failure, or hospitalization should report it.

For additional details, consult the official Afrezza prescribing information (PDF), review the phase 3 trial results published in BMJ Open Diabetes Research & Care, and refer to the CDC resource on inhaled insulin for patient-focused overviews. Additional guidance on spirometry interpretation can be found in the ATS/ERS technical standards for spirometry.

Conclusion: Balancing Efficacy and Safety

Afrezza is a valuable tool in the diabetes armamentarium, offering a needle-free, rapid-acting insulin option that can improve quality of life for certain patients. However, its unique route of administration demands careful patient selection and ongoing monitoring of pulmonary function. By adhering to FDA-mandated screening, educating patients about potential respiratory signs, and establishing a structured follow-up schedule, healthcare teams can help patients enjoy the benefits of Afrezza while minimizing lung-related risks. As with any diabetes therapy, individualized assessment and close collaboration between the patient, endocrinologist, and primary care physician remain essential to achieving safe and effective outcomes.